Questions

1. Diagnosis & Primary Lesion:
   • Diagnosis: Acne vulgaris.
   • Primary pathognomonic lesion: Comedo (open comedones / "blackheads" and closed comedones / "whiteheads").
2. Pathogenetic Mechanisms:
   • Follicular epidermal hyperkeratinization: Retention hyperkeratosis of the infundibulum leads to microcomedo formation and ostial plugging.
   • Androgen-driven excess sebum production: Sebaceous gland hyperactivity stimulated by circulating and intracutaneous androgens (dehydroepiandrosterone sulfate, dihydrotestosterone).
   • Proliferation of Cutibacterium acnes (formerly Propionibacterium acnes): Anaerobic microenvironment within the plugged sebaceous follicle promotes bacterial colonization.
   • Host inflammatory and immunological response: C. acnes hydrolyzes sebum triglycerides into free fatty acids and stimulates Toll-like receptor 2 (TLR-2) on monocytes/neutrophils, triggering secretion of pro-inflammatory cytokines (IL-1, IL-8, IL-12, TNF-$\alpha$).
3. Clinical Grading System:
   • Grade 1 (Mild): Predominantly open and closed comedones with occasional superficial papules; no nodules.
   • Grade 2 (Moderate): Erythematous inflammatory papules and pustules (15–50 lesions) accompanied by comedones.
   • Grade 3 (Severe): Numerous inflammatory papules, pustules, and occasional painful nodules/cysts (>50 lesions, or $\ge$5 nodules).
   • Grade 4 (Very severe / Conglobata): Extensive coalescing nodulocystic lesions, draining sinus tracts, and destructive scarring.
4. Pharmacological Management (Grade 2 Moderate Disease):
   • Topical Retinoid: Adapalene 0.1% gel (or Tretinoin 0.025%–0.05% cream) applied thinly to the entire affected face once daily at bedtime.
   • Topical Antimicrobial: Benzoyl peroxide 2.5% to 5% gel applied once daily in the morning to prevent bacterial resistance and reduce inflammatory lesions.
   • Systemic Antibiotic (if topical therapy inadequate after 6–8 weeks): Oral Doxycycline $2\text{ mg/kg/day}$ (administered as $100\text{ mg}$ once daily) taken with a full glass of water after food for a restricted duration of 8 to 12 weeks. Always co-prescribe with topical benzoyl peroxide; avoid oral antibiotic monotherapy.

1. Diagnosis & Culprit Contactants:
   • Unifying Diagnosis: Allergic Contact Dermatitis (ACD).
   • Patient A contactant: Acrylates / rubber accelerators / colophony (rosin) present in surgical adhesive tape.
   • Patient B contactant: Nickel (nickel sulfate) present in the metallic belt buckle.
2. Immunological Hypersensitivity Mechanism:
   • Classification: Gel and Coombs Type IV (delayed-type, cell-mediated) hypersensitivity reaction.
   • Sensitization Phase: Low-molecular-weight chemical (hapten) penetrates the stratum corneum, complexes with epidermal carrier proteins, and is internalized by epidermal Langerhans cells. Langerhans cells migrate via lymphatic vessels to paracortical zones of regional lymph nodes, presenting the hapten-protein complex via MHC Class II to naive CD4+ T-lymphocytes (and MHC Class I to CD8+ T cells), driving the generation and clonal expansion of hapten-specific memory T cells (takes 10 to 14 days).
   • Elicitation Phase: Upon subsequent cuticular re-exposure, the hapten is processed and presented to circulating memory T cells within the dermis and epidermis. Activated T cells release pro-inflammatory cytokines (IFN-$\gamma$, TNF-$\alpha$, IL-1, IL-2), recruiting monocytes, macrophages, and neutrophils, which induce spongiosis, intraepidermal vesiculation, and dermal inflammatory infiltration within 24 to 72 hours.
3. Confirmatory Diagnostic Test:
   • Patch Testing (e.g., Thin-Layer Rapid Use Epicutaneous [TRUE] test or Indian Standard Battery).
   • Reading Timetable: Patches are applied to intact upper back skin for 48 hours; first reading is performed 30 minutes after removal at 48 hours (Day 2); second reading is conducted at 72 to 96 hours (Day 3 or 4); optional delayed reading at Day 7 to detect late-reacting haptens (e.g., neomycin, corticosteroids).
4. Acute Pharmacological Management:
   • Barrier removal: Immediate discontinuation and avoidance of all adhesive tapes; cleanse area with isotonic saline.
   • Symptomatic topical compresses: Saline-soaked cool compresses applied for 15 minutes 3–4 times daily to reduce weeping and vesicular crusting.
   • Topical Corticosteroid: Mid-potency topical corticosteroid, such as Mometasone furoate 0.1% cream or Fluticasone propionate 0.05% cream, applied thinly once daily for 7 to 10 days.
   • Oral Antihistamine (for pruritus): Cetirizine $0.25\text{ mg/kg/day}$ (or $5\text{ mg}$ once daily orally) at bedtime.

1. Diagnosis & Pathognomonic Trichoscopic Finding:
   • Diagnosis: Alopecia areata.
   • Trichoscopic feature: Exclamation mark hairs (short, fractured hairs tapered and hypopigmented at the proximal scalp insertion with a wider, darker distal tip). Additional findings include black dots, yellow dots, and short vellus hairs.
2. Differential Diagnosis Matrix:
   • Versus Tinea Capitis: Tinea capitis exhibits fine epidermal scaling, boggy swelling (kerion), dull/lustreless broken hair stumps at follicle mouths, and regional posterior cervical or occipital lymphadenopathy (all absent in alopecia areata).
   • Versus Trichotillomania: Trichotillomania demonstrates bizarre, geometrically irregular, incomplete patches containing hairs broken at varying lengths, devoid of exclamation point hairs, and typically exhibits a negative hair pull test.
   • Alopecia Areata Hallmark: Perfectly smooth, completely bald, non-inflammatory skin patch (non-cicatricial alopecia) with preserved follicular ostia.
3. Immunopathogenesis:
   • Collapse of hair follicle immune privilege: Anagen-stage hair bulbs normally enjoy immune privilege via low/absent expression of MHC Class I and II antigens and production of local immunosuppressive factors (TGF-$\beta$, $\alpha$-MSH).
   • In alopecia areata, ectopic upregulation of MHC Class I (HLA-A, B, C) and Class II molecules on follicular epithelium is driven by interferon-gamma (IFN-$\gamma$).
   • This provokes an autoantigen-specific autoimmune attack by CD8+ cytotoxic T cells and NKG2D+ natural killer cells, forming a dense peribulbar lymphocytic infiltrate ("swarm of bees" appearance on biopsy).
   • This halts hair matrix keratinocyte proliferation and forces premature transition from anagen (growth) into catagen/telogen (involution/resting) phase without permanently destroying the follicular stem cells.
4. Hair Pull Test:
   • Technique: Approximately 50 to 60 scalp hairs are firmly grasped between the thumb, index, and middle fingers at the scalp surface and pulled steadily away from the scalp along the hair shaft axis.
   • Positive Result: Extraction of $>6$ hairs (or $>10\%$ of grasped hairs) without pain denotes telogen/dystrophic anagen fragility, signifying active, expanding disease.
5. First-line Therapy (<50% Scalp Involvement in Children <10 Years):
   • Potent Topical Corticosteroid: Mometasone furoate 0.1% cream/lotion or Betamethasone dipropionate 0.05% lotion applied once daily to bald patches for 6 to 12 weeks.
   • Alternative/Adjunct: Topical Minoxidil 2% or 5% solution applied twice daily to accelerate anagen re-entry.
   • (Note: Intralesional triamcinolone acetonide injections [$2.5\text{ to }5\text{ mg/mL}$] are reserved for older adolescents due to procedural pain and risk of dermal atrophy).

1. Diagnosis:
   • Borderline Tuberculoid (BT) Hansen's disease (Leprosy), not in reaction.
2. Bedside Sensory Testing Protocol:
   • Temperature Sensation (earliest to be lost): Two test tubes filled with warm water ($40^\circ\text{C}$) and cold water ($10^\circ\text{C}$) are touched alternately to the skin inside the patch versus normal surrounding skin while the

1. Most Likely Diagnosis:

   • Congenital Melanocytic Nevus (CMN) (or Giant Congenital Melanocytic Nevus).

2. Differential Diagnoses:

   • Becker nevus (pigmented hairy epidermal nevus)
   • Nevus of Ota (oculodermal melanocytosis) / Nevus of Ito
   • Congenital dermal melanocytosis (Mongolian spot)
   • Plexiform neurofibroma (Neurofibromatosis type 1)
   • Cellular blue nevus
   • Epidermal nevus (verrucous or linear epidermal nevus)

3. Classification and Associated Complications:

   • Classification by Projected Adult Size (PAS):
     • Small: $< 1.5\text{ cm}$
     • Medium ($M$): $1.5\text{ to } 19.9\text{ cm}$ ($M_1: 1.5\text{--}10\text{ cm}$; $M_2: > 10\text{--}20\text{ cm}$)
     • Large ($L$): $20\text{ to } 39.9\text{ cm}$ ($L_1: 20\text{--}30\text{ cm}$; $L_2: > 30\text{--}40\text{ cm}$)
     • Giant ($G$): $\ge 40\text{ cm}$ (or requiring multi-stage excision)
   • Primary Life-Threatening Complications:
     • Cutaneous Malignant Melanoma: Lifetime risk of approximately $2\%\text{ to }5\%$ in large/giant CMN (frequently developing deep within the dermis or subcutaneous tissue rather than at the dermoepidermal junction).
     • Neurocutaneous Melanosis (NCM): Proliferation of melanocytes within the leptomeninges and brain parenchyma, predisposing to hydrocephalus, refractory seizures, neurodevelopmental regression, and central nervous system melanoma.

4. Management and Surveillance Protocol:

   • Neurological Evaluation & Neuroimaging:
     • Clinical screening for signs of raised intracranial pressure, seizures, or focal deficits.
     • Contrast-enhanced MRI of the brain and entire spine is indicated for high-risk lesions (axial/head/neck location, PAS $>20\text{ cm}$, or $\ge 3$ satellite nevi), ideally performed in early infancy (before complete myelination) or at initial presentation if symptomatic.
   • Serial Cutaneous Surveillance:
     • Lifelong photographic documentation and dermatoscopic monitoring every 6 to 12 months.
     • Palpation of the entire lesion at each visit to detect deep dermal/subcutaneous nodules.
     • Education on the ABCDE criteria (Asymmetry, Border irregularity, Color variegation, Diameter, Evolution) and prompt reporting of new nodules, bleeding, ulceration, or rapid regional thickening.
   • Surgical & Interventional Considerations:
     • Full-thickness excisional biopsy of any rapidly changing, ulcerated, or clinically suspicious nodular areas.
     • Prophylactic surgical excision (staged resection, tissue expanders, or skin grafting) may be considered for functional impairment or cosmetic disfigurement, but patients and parents must be counseled that surgical excision does not completely eliminate the risk of extracutaneous/CNS melanoma.
   • Psychosocial Support:
     • Comprehensive counseling regarding body image, stigma, and school/social adaptation during adolescence.

1. Posterior axial location (scalp, neck, paravertebral area, buttocks).
2. Projected adult diameter $> 20\text{ cm}$.
3. Presence of multiple satellite nevi (especially $> 20$ satellite lesions).

Molecular Genetics:
Somatic post-zygotic gain-of-function mutations in the NRAS gene (predominantly codon 61, Q61K or Q61R) drive the majority ($> 75\%$) of large and giant congenital melanocytic nevi, while a smaller subset is driven by somatic BRAF (V600E) mutations. Targeted therapies (e.g., MEK inhibitors) are under investigation for unresectable, symptomatic neurocutaneous melanosis.

1. Diagnosis:
   • Cutis marmorata (physiologic mottling of the newborn).
2. Pathophysiology:
   • Normal physiological vasomotor response of the neonatal cutaneous microcirculation to cold ambient stress.
   • Results from an immature autonomic nervous system regulating the dermal vascular plexus.
   • Cold exposure induces simultaneous reflex vasoconstriction of dermal arterioles and passive dilatation of superficial postcapillary venules, producing an alternating red-blue reticulated pattern.
3. Distinction from CMTC:
   • Response to temperature: Cutis marmorata promptly resolves with skin rewarming; CMTC persists unchanged despite warming.
   • Distribution and morphology: Cutis marmorata is generalized and symmetric without skin breakdown; CMTC is typically localized/segmental, often asymmetric, deeper violaceous, and can exhibit epidermal atrophy or ulceration.
   • Associated anomalies: Cutis marmorata is an isolated benign phenomenon; CMTC is associated with extracutaneous anomalies in up to 50% of cases (e.g., limb length discrepancy, body asymmetry, vascular malformations, glaucoma).
4. Management and Prognosis:
   • Management: Reassurance of parents, maintenance of a neutral thermal environment, avoidance of cold stress, and swaddling. No pharmacological therapy required.
   • Prognosis: Completely benign; spontaneously resolves within the first several weeks to months of life as cutaneous autonomic vasomotor regulation matures.

1. Clinical Diagnosis:
   • Epidermolysis bullosa (EB; mechanobullous disease spectrum).
2. Classification by Cleavage Level:
   • EB Simplex (EBS): Intraepidermal cleavage (within basal keratinocytes; KRT5, KRT14 mutations).
   • Junctional EB (JEB): Intralamina lucida cleavage (dermal-epidermal basement membrane; LAMA3, LAMB3, LAMC2, COL17A1 mutations).
   • Dystrophic EB (DEB): Sublamina densa cleavage (upper papillary dermis below lamina densa; COL7A1 mutations).
   • Kindler Syndrome: Mixed/multiple cleavage planes (intraepidermal, junctional, and dermal; FERMT1 mutations).
3. Inheritance and Recurrence Risk:
   • (a) EB Simplex:
     • Mode of inheritance: Autosomal dominant (majority).
     • Recurrence risk: 50% (1 in 2) if a parent is affected; near population baseline (with ~1–2% risk due to germline mosaicism) if resulting from a de novo mutation in clinically unaffected parents.
   • (b) Junctional EB (Severe generalized / Herlitz):
     • Mode of inheritance: Autosomal recessive.
     • Recurrence risk: 25% (1 in 4) for each subsequent pregnancy between obligate carrier parents.
4. Wound Care and Handling Principles:
   • Atraumatic handling: Never lift infant under axillae; roll onto a padded foam mattress or transfer using silk sheets.
   • Blister decompression: Puncture blisters at dependent margins with a sterile needle leaving the overlying blister roof intact as a biological barrier; never de-roof blisters.
   • Non-adherent dressings: Apply lipidocolloid or soft silicone contact layers (e.g., Mepitel); strictly avoid standard adhesive tapes or plasters directly on skin.
   • Diaper modification: Line diaper waistbands and elastic leg cuffs with soft cotton padding or soft paraffin-impregnated gauze; loosely fasten diapers.

1. Diagnosis:
   • LEOPARD syndrome (Noonan syndrome with multiple lentigines [NSML]).
2. Acronym Components:
   • L: Lentigines (multiple cutaneous dark brown macules).
   • E: Electrocardiographic conduction abnormalities (e.g., prolonged PR interval, bundle branch block, Q-wave abnormalities).
   • O: Ocular hypertelorism.
   • P: Pulmonic stenosis.
   • A: Abnormalities of genitalia (e.g., cryptorchidism, hypospadias, gonadal dysgenesis).
   • R: Retardation of growth (short stature).
   • D: Deafness (sensorineural hearing loss).
3. Genetic Etiology:
   • Gene: PTPN11 mutation (in ~85% of cases; less commonly RAF1 or BRAF).
   • Protein: SHP2 (Src homology-2 domain-containing protein tyrosine phosphatase).
   • Signaling Pathway: RAS-MAPK (mitogen-activated protein kinase) signaling cascade (categorized as a "Rasopathy").
4. Frequent Cardiac Lesions:
   • Hypertrophic cardiomyopathy (HCM; most common, observed in up to 70–80% of affected patients, often biventricular or asymmetric septal).
   • Pulmonary valve stenosis (PS; seen in ~25–30% of patients, frequently dysplastic).

1. Diagnosis:
   • Linear IgA bullous dermatosis of childhood (LABD) / Chronic bullous disease of childhood (CBDC).
2. Morphological Pattern:
   • "String of pearls" sign.
   • "Cluster of jewels" sign (or "rosette-like" configuration).
3. Direct Immunofluorescence (DIF):
   • Continuous, homogeneous, linear deposition of IgA along the basement membrane zone (BMZ) / dermo-epidermal junction.
4. Pharmacotherapy and Calculations:
   • Drug of Choice: Oral Dapsone (diaminodiphenyl sulfone).
   • Mandatory Pre-treatment Workup:
     • Glucose-6-Phosphate Dehydrogenase (G6PD) assay (to prevent life-threatening drug-induced hemolysis).
     • Complete blood count with differential and reticulocyte count (baseline for agranulocytosis and hemolytic anemia monitoring).
   • Dose Calculation:
     • Target therapeutic dose range: $1\text{ to }2\text{ mg/kg/day}$ (initial starting dose: $0.5\text{ mg/kg/day}$).
       $$ > \begin{aligned} > \text{Daily Target Dose} &= 1\text{ to }2\text{ mg/kg/day} \times 18\text{ kg} \\ > &= \mathbf{18\text{ to }36\text{ mg/day}} \quad (\text{given orally in 1 to 2 divided doses}) > \end{aligned} > $$

1. Diagnosis and Morphology:
   • Diagnosis: Molluscum contagiosum.
   • Morphological term: Central umbilication (delle / central punctum).
2. Causative Organism:
   • Pathogen: Molluscum contagiosum virus (MCV; MCV-1 is the most common pediatric serotype).
   • Classification: Large, enveloped, double-stranded DNA (dsDNA) virus.
   • Family: Poxviridae (genus Molluscipoxvirus).
3. Histopathology:
   • Henderson-Paterson bodies (molluscum bodies: large, intracytoplasmic, oval, eosinophilic inclusions in stratum spinosum that turn deeply basophilic in the stratum granulosum).
4. Therapy and Complication:
   • Active Therapeutic Modalities (any 3):
     • Topical cantharidin (0.7% solution applied strictly to lesions and washed off after 2–4 hours).
     • Cryotherapy with liquid nitrogen (5–10 second application).
     • Gentle mechanical curettage or manual expression of the central curd-like core under topical local anesthesia (EMLA).
     • Topical potassium hydroxide (KOH 10% solution applied daily until micro-inflammation develops).
     • Topical imiquimod (5% cream applied 3 nights per week).
   • Cutaneous Complication:
     • Eczema molluscatum (extensive, widespread dissemination of molluscum lesions across compromised, eczematous skin).

1. Clinical Diagnoses:
   • Image A: Erythema toxicum neonatorum (ETN)
   • Image B: Neonatal cephalic pustulosis (benign cephalic pustulosis / neonatal acne)
2. Cytological Characteristics (Tzanck / Wright-Giemsa Smear):
   • Image A (ETN): Marked predominance of eosinophils (>90% of inflammatory infiltrate); absence of bacteria or fungi.
   • Image B (Neonatal cephalic pustulosis): Predominance of neutrophils, occasional lipid droplets, and yeast forms of Malassezia species (Malassezia sympodialis or Malassezia furfur); absence of true comedones.
3. Onset and Natural History:
   • Erythema toxicum neonatorum: Typically appears at 24–48 hours of life (rarely present at birth); individual lesions wax and wane within hours, with complete spontaneous resolution within 7–14 days.
   • Neonatal cephalic pustulosis: Typically appears at 2–3 weeks of age; self-limiting course resolving spontaneously within 1 to 3 months without scarring.
4. Management Protocol:
   • Erythema toxicum neonatorum: Parental reassurance and observation; no topical or systemic pharmacotherapy is warranted.
   • Neonatal cephalic pustulosis:
     • Routine care: Gentle cleansing with mild soap and warm water once daily; avoid heavy oils and ointments.
     • Mild/moderate persistent cases: Topical 2% ketoconazole cream applied twice daily for 7–14 days, or topical 1% hydrocortisone cream once daily for up to 5 days if severe inflammation is present.

1. Clinical Diagnosis:
   • Neurofibromatosis Type 1 (NF1 / von Recklinghausen disease).
2. Genetic Basis:
   • Inheritance: Autosomal dominant with complete penetrance and variable expressivity (~50% represent de novo pathogenic variants).
   • Gene & Locus: Loss-of-function mutation or microdeletion in the NF1 gene located on chromosome 17q11.2, which encodes the tumor suppressor protein neurofibromin (a negative regulator of the RAS/MAPK pathway / Ras-GTPase-activating protein).
3. Revised (2021) International Diagnostic Criteria for NF1 (requires ≥2 of the following in an individual without an affected parent; or ≥1 in an individual with a parent meeting criteria):
   • ≥6 Café-au-lait macules (>5 mm in greatest diameter in prepubertal individuals, >15 mm in postpubertal individuals).
   • Freckling in the axillary or inguinal regions (Crowe sign).
   • ≥2 neurofibromas of any type OR ≥1 plexiform neurofibroma.
   • Optic pathway glioma.
   • ≥2 Lisch nodules (iris hamartomas) identified on slit-lamp examination OR ≥2 choroidal abnormalities (bright, patchy nodules seen on near-infrared reflectance imaging).
   • A distinctive osseous lesion: sphenoid wing dysplasia, anterolateral bowing of the tibia (tibial pseudarthrosis), or thinning of long bone cortex.
   • A heterozygous pathogenic NF1 gene variant with a variant allele fraction of 50% in normal tissue.
4. Associated Signs:
   • Ophthalmological signs: Lisch nodules (iris hamartomas), choroidal abnormalities, optic pathway glioma.
   • Skeletal abnormalities: Sphenoid wing dysplasia, anterolateral tibial bowing / congenital pseudarthrosis of the tibia, severe dystrophic scoliosis, pectus excavatum/carinatum.

1. Primary Differential Diagnoses:
   • Nevus achromicus (nevus depigmentosus)
   • Nevus anemicus
2. Differentiating Bedside Maneuver (Diascopy & Friction Test):
   • Diascopy (Glass slide compression):
     • Nevus anemicus: Under glass slide pressure applied to the lesion and surrounding normal skin, the erythema in the surrounding skin blanches, causing the lesion to merge completely with the adjacent pale compressed skin (the lesion becomes imperceptible).
     • Nevus achromicus: The borders remain distinct and clearly demarcated from the surrounding blanched skin during diascopy.
   • Friction / Stroking Test:
     • Nevus anemicus: Rubbing or scratching the lesion fails to produce an erythematous flare within the patch due to localized vascular hyper-reactivity, whereas surrounding skin develops normal wheal/flare (spared from flare).
     • Nevus achromicus: Rubbing induces erythema across both the patch and the surrounding skin.
3. Histopathological and Pathophysiological Distinction:
   • Nevus achromicus: Structural pigmentary defect characterized by normal or slightly reduced numbers of melanocytes, but defective transfer and aggregation of mature melanosomes into surrounding keratinocytes (functional hypomelanosis).
   • Nevus anemicus: Pharmacological/vascular defect characterized by localized vessel hypersensitivity to circulating catecholamines leading to permanent microvascular vasoconstriction via hyper-responsive alpha-adrenergic receptors; melanocytes and melanin synthesis are entirely normal.
4. Prognosis and Management:
   • Prognosis: Both lesions are benign, stable in shape and proportional size, and persist throughout life without malignant transformation.
   • Management: Reassurance; no active medical or surgical therapy is required. Cosmetic camouflage creams or sunscreens (to avoid tanning of surrounding skin) may be advised.

1. Clinical Diagnosis:
   • Nummular eczema (discoid eczema).
2. Differential Diagnoses:
   • Tinea corporis (ruled out by negative KOH mount)
   • Plaque psoriasis
   • Allergic contact dermatitis
   • Pityriasis rosea (herald patch or secondary plaques)
   • Impetigo (crusted forms)
3. Secondary Complications:
   • Secondary bacterial infection (impetiginization, predominantly Staphylococcus aureus or Streptococcus pyogenes).
   • Post-inflammatory hyperpigmentation or hypopigmentation.
   • Lichen simplex chronicus secondary to habitual rubbing/scratching.
4. Management Plan:
   • General/Barrier Measures:
     • Soap-free synthetic detergents (syndets) for brief, lukewarm baths.
     • Liberal application of thick, fragrance-free emollient ointments (e.g., white soft paraffin or ceramide-based ointments) within 3 minutes after bathing ("soak and seal").
     • Humidification of dry indoor air and avoidance of wool or rough clothing.
   • Topical Anti-inflammatory Therapy:
     • Mid-to-high potency topical corticosteroid: Mometasone furoate 0.1% ointment or Fluticasone propionate 0.05% ointment applied once daily to active plaques for 2–3 weeks, tapering to alternate days as lesions clear.
     • Maintenance/Steroid-sparing: Topical calcineurin inhibitors (Tacrolimus 0.03% or 0.1% ointment) twice daily once acute inflammation has settled.
   • Infection & Pruritus Control:
     • If crusting/weeping indicates secondary impetiginization: Oral Cephalexin (25–50 mg/kg/day divided q6–8h) or topical Mupirocin 2% ointment thrice daily for 5–7 days.
     • Oral second-generation antihistamine (e.g., Cetirizine 5–10 mg once daily) or sedating antihistamine at bedtime (e.g., Hydroxyzine 1 mg/kg/dose) to break the nocturnal itch-scratch cycle.

1. Clinical Diagnosis:
   • Pityriasis alba.
2. Morphology and Distribution:
   • Morphology: Ill-defined, round or oval hypopigmented patches with irregular margins, often preceded by faint erythema and covered with fine, delicate, powdery ("branny") scales; non-atrophic without loss of cutaneous sensation.
   • Distribution: Most frequently located on the face (cheeks, forehead, chin); less commonly affects the neck, upper arms, and trunk.
3. Associated Condition and Demographics:
   • Associated Condition: Atopic diathesis / Atopic dermatitis (considered a minor cutaneous hallmark of atopy).
   • Age Group: Children and young adolescents, most commonly between 3 and 16 years of age.
4. Differential Diagnoses:
   • Pityriasis versicolor (KOH mount demonstrates "spaghetti and meatballs" hyphae and spores).
   • Post-inflammatory hypopigmentation (history of preceding overt dermatitis, trauma, or infection).
   • Vitiligo (sharply demarcated, completely depigmented amelanotic chalky-white macules, accentuates bright white under Wood's lamp).
   • Indeterminate leprosy (hypopigmented patch with impairment of thermal, light touch, or pain sensation).
5. Management Strategy:
   • Parental Counseling: Reassure regarding benign, non-contagious nature and eventual complete repigmentation, which may require several months.
   • Sun Protection: Broad-spectrum sunscreen (SPF ≥30) daily to prevent tanning of surrounding unaffected skin, which accentuates contrast.
   • Barrier Repair: Regular and frequent application of bland emollient creams (e.g., petrolatum-based or ceramide-containing moisturizers) to combat xerosis and restore stratum corneum hydration.
   • Anti-inflammatory Therapy (if symptomatic or inflamed):
     • Low-potency topical corticosteroid: Hydrocortisone 1% cream applied once or twice daily for 7 to 14 days.
     • Topical calcineurin inhibitors: Pimecrolimus 1% cream or Tacrolimus 0.03% ointment twice daily as steroid-sparing alternatives on the delicate facial skin.

1. Diagnosis:
   • Pityriasis rosea (a benign, self-limiting, papulosquamous disorder).
2. Initial Lesion & Morphological Scale:
   • Name: Herald patch (mother patch), typically 2 to 5 cm in diameter.
   • Scaling feature: "Collarette" of fine scale that is attached at the periphery and free-floating centrally, directed inward toward the center of the plaque.
3. Distribution Pattern:
   • Arranged symmetrically along the cleavage lines of the skin (Langer lines), classically producing a "fir-tree" or "Christmas-tree" appearance over the back and posterior thorax.
4. Etiology and Management:
   • Etiology: Systemic reactivation of Human Herpesvirus 6 (HHV-6) and Human Herpesvirus 7 (HHV-7).
   • Management:
     • Patient and family reassurance: Self-limiting condition that resolves spontaneously within 6 to 8 weeks; non-contagious.
     • Symptomatic relief: Oral antihistamines (e.g., Cetirizine 0.25 mg/kg/day once daily, max 10 mg/day) and mild-to-moderate topical corticosteroids (e.g., 1% Hydrocortisone or 0.05% Desonide cream applied twice daily) for pruritus.
     • Severe or extensive cases: Oral erythromycin (250 mg four times daily or 40–50 mg/kg/day in divided doses for 14 days) or oral acyclovir (400–800 mg 5 times daily for 7 days) can hasten lesion resolution.

1. Diagnosis:
   • Pityriasis versicolor (achromic / hypopigmented variant; Tinea versicolor).
2. Causative Organisms & State:
   • Malassezia species: Malassezia globosa (most frequent), Malassezia sympodialis, Malassezia furfur, and Malassezia restricta.
   • They exist as normal lipophilic, commensal yeasts of the cutaneous stratum corneum microflora, transforming from the yeast phase into a dimorphic mycelial/hyphal parasitic phase under favorable environmental conditions (heat, humidity, oily skin, immunosuppression).
3. Signs and Bedside Diagnostics:
   • Clinical sign: Besnier sign (Coup d'ongle sign / scratch sign) — gentle scraping produces fine, furfuraceous, branny scale.
   • Wood lamp examination: Yellowish-gold or pale yellow-orange fluorescence under ultraviolet light (365 nm) due to pityrialactone.
   • 10–20% KOH Mount: "Spaghetti and meatballs" appearance (short, stout, angular unbranched hyphae mixed with clusters of thick-walled spherical yeast cells).
4. Biochemical Mechanism of Hypopigmentation:
   • The mycelial form of Malassezia synthesizes and secretes dicarboxylic acids, predominantly azelaic acid, which competitively inhibits tyrosinase within melanocytes and exerts a direct cytotoxic effect on melanocytes, reducing melanin transfer to keratinocytes.
5. Treatment Protocol:
   • Topical (First-line):
     • 2.5% Selenium sulfide suspension or 2% Ketoconazole shampoo applied to affected areas from the neck to knees, left for 10–15 minutes, then rinsed off, daily for 14 days; followed by once-monthly maintenance during humid months.
     • Alternative: Topical 1% Clotrimazole or 2% Ketoconazole cream applied twice daily for 2 to 3 weeks.
   • Systemic (Reserved for extensive, refractory, or recurrent disease):
     • Oral Fluconazole: $3\text{ to }6\text{ mg/kg/week}$ (maximum 300 mg) as a single weekly dose for 2 to 4 weeks, OR
     • Oral Itraconazole: $3\text{ to }5\text{ mg/kg/day}$ (100–200 mg once daily) with food for 7 days.
     • Patient counseling: Inform the patient that repigmentation takes several months after mycological cure.

1. Diagnosis:
   • Polymorphic light eruption (PMLE) / Polymorphous light eruption.
2. Pathophysiology:
   • A delayed-type hypersensitivity reaction (Type IV cell-mediated immunity) directed against an endogenous, novel cutaneous neoantigen induced by solar ultraviolet radiation (predominantly UVA, 320–400 nm; occasionally UVB, 290–320 nm).
   • Affected individuals exhibit a failure of normal UV-induced local cutaneous immunosuppression (deficient Langerhans cell depletion and impaired regulatory T-cell trafficking).
3. Morphological Variants:
   • Plaque-type (erythematous infiltrated plaques)
   • Papulovesicular / vesiculobullous type
   • Lichenoid type
   • Erythema multiforme-like / targetoid type
   • Insect bite-like (urticarial / prurigo-like)
4. Key Differential Diagnoses:
   • Systemic Lupus Erythematosus (SLE) / Cutaneous LE (Malar rash / subacute cutaneous LE)
   • Hydroa vacciniforme (EBV-associated scarring photodermatosis)
   • Solar urticaria (immediate wheals developing within minutes of exposure)
   • Phototoxic / photoallergic contact dermatitis
   • Erythropoietic protoporphyria (EPP)
5. Management Strategy:
   • Broad-spectrum Photoprotection:
     • Broad-spectrum sunscreens protecting against both UVA and UVB with Sun Protection Factor (SPF) $\ge 50$ and high UVA-PF (PA++++), applied liberally 20 minutes prior to outdoor exposure and reapplied every 2 hours.
     • Protective clothing (UPF-rated long sleeves, wide-brimmed hats) and mid-day sun avoidance (10:00 AM to 4:00 PM).
   • Acute Symptomatic Pharmacotherapy:
     • Topical Corticosteroid: Moderate-potency topical steroid (e.g., Mometasone furoate 0.1% cream or Hydrocortisone butyrate 0.1% cream) applied once or twice daily to inflamed lesions for 5 to 7 days.
     • Oral Antihistamine: Hydroxyzine $1\text{ to }2\text{ mg/kg/day}$ in 2–3 divided doses or Levocetirizine $0.125\text{ mg/kg/day}$ once daily for pruritus.
     • Severe flares: Short course of oral Prednisolone ($0.5\text{ to }1\text{ mg/kg/day}$ tapered over 7–10 days).
   • Prophylactic "Hardening":
     • Gradual, controlled natural sun exposure or prophylactic phototherapy (narrowband UVB or PUVA) administered in early spring to induce immune tolerance ("hardening" phenomenon).

1. Clinical Finding:
   • Polythelia (supernumerary nipple / accessory nipple).
2. Embryological Basis:
   • Structure: The mammary ridge (milk line).
   • Timeline & Fate: Develops during the 4th to 6th week of human embryonic life as a bilateral ectodermal band thickening running ventrolaterally from the axillae downward to the medial groin/inguinal regions.
   • Normal fate: The milk line normally regresses completely by the 9th week of gestation, except in the 4th intercostal space of the pectoral region where the definitive pair of breasts develops. Incomplete regression of ectodermal remnants along this path results in supernumerary nipples.
3. Polythelia vs. Polymastia:
   • Polythelia: Presence of an accessory nipple and/or areola without any underlying glandular breast tissue (mammary parenchyma).
   • Polymastia: Presence of accessory glandular breast tissue, with or without an overlying nipple-areola complex, which undergoes physiological hormone-responsive changes during puberty, pregnancy, and lactation.
4. Systemic Associations and Recommended Evaluation:
   • Reported associations: Congenital anomalies of the kidney and urinary tract (CAKUT, e.g., renal agenesis, duplex collecting system, hydronephrosis) and cardiovascular malformations (e.g., ventricular septal defects, arrhythmias).
   • Current practice: Routine screening renal ultrasonography or echocardiography is not recommended in an isolated, asymptomatic, non-syndromic child with polythelia. Detailed history and thorough physical examination (blood pressure, spine, dysmorphism) are performed; imaging is reserved only if other dysmorphic features or clinical signs/symptoms of renal/cardiac disease exist.

1. Clinical Finding:
   • Accessory tragus (preauricular skin tag / cartilaginous choristoma / polyotia).
2. Embryological Pathophysiology:
   • Formed due to the abnormal development, cleavage, or failure of fusion of the first branchial (pharyngeal) arch (mandibular arch) mesenchyme, specifically derived from the first and second anterior hillocks of His during the 6th to 9th weeks of embryonic life.
3. Differential Diagnosis:
   • Preauricular fibroma / Acrochordon (skin tag without a cartilaginous core)
   • Epidermal inclusion cyst
   • First branchial cleft anomaly (cyst, sinus, or fistula)
   • Preauricular sinus / pit with granuloma
   • Neurofibroma
4. Syndromic Associations:
   • Goldenhar syndrome (Oculo-auriculo-vertebral spectrum / hemifacial microsomia)
   • Treacher Collins syndrome (Mandibulofacial dysostosis)
   • Townes-Brocks syndrome
   • VACTERL association
5. Management & Surgical Precaution:
   • Definitive Treatment: Elective surgical excision under local or general anesthesia (typically deferred until 6 to 12 months of age).
   • Surgical Precaution: Simple ligation (tying off) with a suture at the base must never be performed because the underlying cartilaginous core frequently extends deep through the subcutaneous fat to the perichondrium or tragal cartilage. Ligation leaves an exposed, protruding cartilaginous bar that can cause non-healing ulceration, chondritis, painful neuroma, or unsightly puckering. Complete surgical excision with sub-dermal resection of the entire cartilaginous stalk flush with deep fascial layers is required.

1. Diagnosis:
   • Purpura fulminans (Acute infectious purpura fulminans secondary to severe septic shock and Disseminated Intravascular Coagulation [DIC]).
2. Bacterial Etiologies:
   • Neisseria meningitidis (meningococcemia; most common cause)
   • Streptococcus pneumoniae
   • Staphylococcus aureus (particularly toxin-producing strains)
   • Haemophilus influenzae type b (Hib)
   • Capnocytophaga canimorsus (following dog bites/scratches, especially in asplenia)
3. Pathophysiology:
   • Endotoxin- and inflammatory cytokine-mediated (TNF-$\alpha$, IL-1, IL-6) endothelial cell damage downregulates thrombomodulin and endothelial protein C receptor (EPCR).
   • Severe acute consumption and secondary depletion of circulating endogenous natural anticoagulants (Protein C, Protein S, and Antithrombin III).
   • Uncontrolled thrombin generation produces widespread microvascular thrombosis in dermal capillaries and postcapillary venules.
   • Secondary tissue ischemia, vascular necrosis, extravasation of erythrocytes, and full-thickness cutaneous hemorrhagic infarction/gangrene ensue.
4. Replacement Volumes and Antimicrobial Regimen:
   $$ > \begin{aligned} > \text{FFP Volume} &= 15\text{ mL/kg} \times 16\text{ kg} = \mathbf{240\text{ mL IV}} \quad (15\text{--}20\text{ mL/kg}) \\ > \text{Platelet Concentrate} &= 10\text{ mL/kg} \times 16\text{ kg} = \mathbf{160\text{ mL IV}} \quad (\approx 2\text{ random donor units}) \\ > \text{Cryoprecipitate} &= 1\text{ unit per }10\text{ kg} \approx \mathbf{2\text{ units IV}} \quad (5\text{--}10\text{ mL/kg to keep fibrinogen } >100\text{ mg/dL}) > \end{aligned} > $$
   • Empiric Antimicrobial Regimen:
     • IV Ceftriaxone: 100 mg/kg/day IV divided q12h (or IV Cefotaxime 200 mg/kg/day divided q6h)
     • IV Vancomycin: 60 mg/kg/day IV divided q6h (for MRSA coverage)

graph TD
    A[Severe Sepsis / Endotoxemia] --> B[Proinflammatory Cytokines: TNF-a, IL-1, IL-6]
    B --> C[Downregulation of Endothelial Thrombomodulin & EPCR]
    C --> D[Profound Consumption of Protein C & Protein S]
    D --> E[Uncontrolled Thrombin Generation]
    E --> F[Widespread Microvascular Thrombosis in Dermis]
    F --> G[Hemorrhagic Infarction & Purpura Fulminans]
    G --> H[Secondary Consumption Coagulopathy & Bleeding]

Protein C replacement concentrate (if available) is dosed at an initial loading dose of 100–120 IU/kg IV, followed by 60–80 IU/kg IV every 6 hours, titrating to maintain trough plasma Protein C activity > 50%.

1. Diagnosis:
   • Staphylococcal Scalded Skin Syndrome (SSSS) / Ritter disease (Ritter von Rittershain disease in neonates).
2. Etiology and Toxins:
   • Organism: Staphylococcus aureus belonging to Phage Group II (strains 55, 71, 3A, 3B, 3C).
   • Exotoxins: Epidermolytic toxins / Exfoliatins:
     • Exfoliative toxin A (ETA): Heat-stable, chromosomal gene.
     • Exfoliative toxin B (ETB): Heat-labile, plasmid-encoded.
3. Molecular Target and Histological Cleavage:
   • Molecular Target: Desmoglein-1 (Dsg-1), an extracellular cadherin-type cell-to-cell adhesion molecule in desmosomes.
   • Cleavage Plane: High intraepidermal separation through the stratum granulosum (subcorneal splitting).
4. Differentiation from Toxic Epidermal Necrolysis (TEN):
   • Clinical:
     • Mucous membranes: Spared in SSSS (mucosa retains Dsg-3 which compensates for Dsg-1 cleavage); severely involved (> 2 mucosal sites with frank ulceration) in TEN.
     • Targetoid lesions: Absent in SSSS; characteristic dusky atypical targets present in TEN.
   • Histological:
     • Cleavage level: Superficial intraepidermal (subcorneal / granular layer) split in SSSS; subepidermal detachment at the dermoepidermal junction in TEN.
     • Keratinocyte necrosis: Minimal/absent epidermal cell death in SSSS; full-thickness epidermal necrosis in TEN.
5. Antimicrobial and Supportive Therapy:
   • Definitive Antibiotic:
     • IV Cloxacillin / Oxacillin: 100–150 mg/kg/day divided q6h for 7–10 days (or IV Cefazolin 50–100 mg/kg/day divided q8h).
     • If Methicillin-Resistant S. aureus (MRSA) suspected: IV Vancomycin 40–60 mg/kg/day divided q6h OR IV Clindamycin 30–40 mg/kg/day divided q8h (clindamycin additionally suppresses ribosomal exotoxin synthesis).
   • Supportive Skin Care:
     • Non-adherent bland petrolatum-impregnated dressings; avoid adhesive tapes.
     • Maintenance of warm ambient environment (30–32°C) to prevent hypothermia.
     • Adequate analgesia (paracetamol/opioids; avoid NSAIDs due to renal and cutaneous clearance risks).

1. Definitive Diagnosis & Pathophysiology:

   • Diagnosis: Kerion (Kerion celsi / inflammatory tinea capitis).
   • Immunopathology: Exaggerated delayed-type (Type IV) cell-mediated hypersensitivity reaction to dermatophyte antigens (commonly zoophilic species such as Trichophyton mentagrophytes or anthropophilic species like Trichophyton tonsurans and Trichophyton violaceum), exacerbated by epidermal microtrauma during tonsure and inappropriate topical immunosuppression.

2. Microscopic & Wood's Lamp Characteristics:

   • 10%–20% KOH Mount: Visualizes fungal hyphae and arthroconidia invading the hair shaft in one of two patterns:
     • Endothrix invasion: Arthroconidia packed strictly inside the hair shaft with an intact cuticle ("bag of marbles" appearance; characteristic of T. tonsurans, T. violaceum).
     • Ectothrix invasion: Dense sheath of arthroconidia coating the external surface of the hair shaft with cuticle destruction (characteristic of Microsporum spp. or T. mentagrophytes).
   • Wood's Lamp Examination:
     • Trichophyton species (T. tonsurans, T. violaceum, T. mentagrophytes): Negative (no fluorescence).
     • Microsporum species (M. canis, M. audouinii): Bright yellow-green fluorescence due to pteridine metabolite.

3. Steroid-Modified Infection (Tinea Incognito):

   • Phenomenon: Tinea incognito (atypical dermatophytosis).
   • Mechanism: High-potency topical corticosteroids suppress local CD4+ Th1-mediated immunity, dampening interferon-gamma (IFN-$\gamma$) and tumor necrosis factor-alpha (TNF-$\alpha$) production. This blunts local erythema, scaling, and classical annular margins while permitting unchecked dermatophyte proliferation and deeper fungal invasion into the hair follicles (granulomatous folliculitis).

4. Definitive Management Plan:

   • Primary Oral Antifungal Calculation (Griseofulvin microsize):
     $$ > \begin{aligned} > \text{Dose} &= 20\text{ to }25\text{ mg/kg/day (single or 2 divided doses)} \\ > \text{Child Weight} &= 20\text{ kg} \\ > \text{Daily Dose} &= 20\text{ kg} \times 20\text{ to }25\text{ mg/kg/day} = \mathbf{400\text{ to }500\text{ mg/day}} \\ > \text{Duration} &= 6\text{ to }8\text{ weeks} \quad (\text{Administered with fatty food/milk for absorption}) > \end{aligned} > $$
     (Alternative: Oral Terbinafine $125\text{ mg once daily}$ for children $20\text{--}40\text{ kg}$ for 4–6 weeks, preferred if Trichophyton confirmed).
   • Adjuvant Oral Corticosteroid: Oral Prednisolone $1\text{ mg/kg/day}$ ($20\text{ mg/day}$) for 10–14 days, given during the first 2 weeks to rapidly abate severe follicular inflammation and prevent permanent cicatricial (scarring) alopecia.
   • Topical Sporicidal Adjunct: 2% Ketoconazole or 1% Selenium sulfide shampoo applied to the scalp 2 to 3 times weekly for 5–10 minutes before rinsing to reduce viable arthroconidial shedding and prevent household spread.
   • Critical Surgical Contraindication: Incision and Drainage (I&D) is strictly contraindicated; kerion is a sterile/inflammatory hypersensitivity mass rather than a bacterial abscess. I&D causes severe permanent scarring, sinus tract formation, and secondary bacterial superinfection.

graph TD
    A[Dermatophyte Inoculation onto Scalp] --> B[Hair Follicle & Cuticle Invasion]
    B --> C{Immune Status & Steroid Exposure}
    C -->|Topical Steroid Misuse| D[Suppression of Th1 Response]
    D --> E[Tinea Incognito: Unchecked Deep Fungal Proliferation]
    E --> F[Massive Type IV Delayed Hypersensitivity]
    C -->|Direct Host Hypersensitivity| F
    F --> G[Kerion Celsi: Boggy Fluctuant Granulomatous Mass]
    G --> H[Systemic Antifungal + Short-Course Steroid]
    G -->|Pitfall: Surgical Incision & Drainage| I[Permanent Scarring Alopecia & Secondary Superinfection]

• Differential Diagnosis:
  • Bacterial carbuncle / scalp abscess (distinguished by acute onset, severe exquisite tenderness, constitutional symptoms, and absence of broken hair stubs).
  • Dissecting cellulitis of the scalp (perifolliculitis capitis abscedens et suffodiens; seen predominantly in post-pubertal males, associated with the follicular occlusion tetrad).
  • Alopecia areata (non-inflammatory, exclamation mark hairs, preserved skin texture without boggy swelling or purulence).
• Monitoring and Cure Criteria:
  • Clinical cure alone is insufficient; therapy must continue until mycological cure is documented via negative repeat KOH mount and fungal culture (Sabouraud Dextrose Agar) at 6–8 weeks.

1. Definitive Clinical Diagnosis:

   • Toxic Epidermal Necrolysis (TEN) / Lyell's syndrome (detachment involves >30% of Total Body Surface Area [TBSA] with multi-mucosal involvement).

2. Differentiation from Staphylococcal Scalded Skin Syndrome (SSSS):

   • Histopathologic Cleavage Plane:
     • TEN: Full-thickness epidermal necrosis with cleavage at the dermo-epidermal junction (subepidermal blister).
     • SSSS: Superficial intraepidermal split through the stratum granulosum (subcorneal cleavage).
   • Mucosal Involvement:
     • TEN: Severe, extensive, and multi-mucosal (oral, ocular, urogenital) in >90% of cases.
     • SSSS: Sparing of mucous membranes (minimal or absent mucosal erythema/erosions).
   • Primary Pathogenesis:
     • TEN: Cell-mediated (CD8+ cytotoxic T lymphocyte and NK cell) immune reaction leading to granulysin- and Fas/Fas-ligand (FasL)-mediated widespread keratinocyte apoptosis.
     • SSSS: Exotoxin-mediated cleavage (Exfoliative toxins A and B produced by Staphylococcus aureus targeting Desmoglein-1).

3. Prognostic Scoring Tool & Variables:

   • SCORTEN (Score of Toxic Epidermal Necrolysis):
     • Age ≥40 years (in adult SCORTEN; ped-SCORTEN evaluates modified thresholds)
     • Tachycardia (Heart rate ≥120 beats/minute)
     • Presence of underlying malignancy
     • Epidermal detachment >10% of TBSA on Day 1
     • Serum Urea / BUN >10 mmol/L (>28 mg/dL)
     • Serum Glucose >14 mmol/L (>252 mg/dL)
     • Serum Bicarbonate <20 mmol/L

4. Implicated Pharmacologic Classes:

   • Aromatic Antiepileptic Drugs (AEDs): Phenytoin, carbamazepine, phenobarbital, lamotrigine.
   • Antimicrobial Sulfonamides: Trimethoprim-sulfamethoxazole (cotrimoxazole), sulfadiazine.
   • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Oxicam derivatives (piroxicam, meloxicam) and aminophenazone derivatives.
   • Antibiotics: Aminopenicillins, cephalosporins, and fluoroquinolones.
   • Xanthine Oxidase Inhibitors: Allopurinol.

5. Management Strategy:

   • Immediate Action: Immediate withdrawal of phenytoin and all other non-essential medications.
   • Admission & Nursing: Transfer to a specialized Pediatric Intensive Care Unit (PICU) or Burn Center; maintain ambient room temperature at 30–32°C to prevent hypothermia; strict barrier nursing.
   • Fluid Resuscitation:
     $$ > \begin{aligned} > \text{24-hour Fluid Requirement} &= 2 \text{ mL} \times \text{Body Weight (kg)} \times \%\text{ TBSA involved} \\ > &= 2 \times 12 \times 50 \\ > &= \mathbf{1200 \text{ mL/day}} \quad (\text{Balanced Crystalloid / Ringer's Lactate}) > \end{aligned} > $$
     • Plus maintenance fluids; titrate to maintain urine output of 1–1.5 mL/kg/h.
   • Wound and Barrier Care: Conservative, non-surgical management; avoid aggressive mechanical debridement; apply non-adherent dressings (e.g., petrolatum-impregnated mesh, silicone dressings, or biosynthetic skin substitutes).
   • Ophthalmic Care: Hourly preservative-free lubricating eye drops, topical antibiotic drops, twice-daily glass rod sweeping / symblepharon lysis to prevent synechiae formation, and amniotic membrane grafting if deep corneal or conjunctival ulceration is present.
   • Specific Immunomodulatory Therapy:
     • Intravenous Immunoglobulin (IVIG): 2 to 3 g/kg total dose infused over 2 to 4 days (inhibits FasL-mediated apoptosis), OR
     • Cyclosporine A: 3 to 5 mg/kg/day orally or IV divided every 12 hours for 10–14 days, then tapered, OR
     • TNF-alpha inhibitor: Etanercept 0.8 mg/kg subcutaneous single dose (max 50 mg).

• Stevens-Johnson Syndrome (SJS): <10% TBSA epidermal detachment.
• SJS/TEN Overlap: 10% to 30% TBSA epidermal detachment.
• Toxic Epidermal Necrolysis (TEN): >30% TBSA epidermal detachment.

Mechanism of Blister Formation:
Clonally expanded cytotoxic T cells (CTLs) and Natural Killer (NK) cells recognize drug-peptide-HLA complexes presented on keratinocytes. The effector cells release granulysin (the primary cytolytic molecule driving disseminated keratinocyte death), perforin, granzyme B, and stimulate FasL/Fas interactions, resulting in massive, synchronous apoptosis of the entire epidermal layer.

1. Diagnosis & Etiology:
   • Clinical Diagnosis: Verruca vulgaris (Common viral wart).
   • Etiologic Agent: Human Papillomavirus (HPV), a non-enveloped, double-stranded circular DNA virus belonging to the family Papillomaviridae.
2. Associated Genotypes:
   • Verruca vulgaris (Common wart): HPV types 2, 4, 27, 57 (also 1, 63).
   • Verruca plantaris (Deep palmoplantar / myrmecia): HPV 1; (mosaic palmoplantar: HPV 2).
   • Verruca plana (Flat wart): HPV types 3, 10, 28.
3. Transmission & Phenomenon:
   • Koebner Phenomenon (Isomorphic response): Linear grouping or appearance of new lesions at sites of microtrauma or scratching.
   • Modes of Transmission: Direct skin-to-skin contact, autoinoculation, or indirect transmission via contaminated fomites (e.g., swimming pool surrounds, communal gym mats, shared towels) through minor epidermal barrier breaches.
4. Management:
   • Keratolytic Therapy (First-Line Topical):
     • Topical Salicylic acid (17% to 40% w/w collodion or plaster): Apply once daily at bedtime following hydration in warm water and gentle debridement of dead keratinized tissue with an emery board or pumice stone. Treatment duration is typically 6–12 weeks.
   • Cryotherapy:
     • Liquid nitrogen (-196°C) application via open spray or cotton bud in 2 freeze-thaw cycles (freeze time of 10–15 seconds until a 1–2 mm halo develops), repeated every 2 to 3 weeks for up to 3–4 sessions.
   • Alternative / Second-Line Agents:
     • Topical Imiquimod 5% cream (immunomodulator) applied 3 times weekly for 6–12 weeks.
     • Cantharidin 0.7% solution applied under occlusive tape for 4–6 hours in clinic.
     • Intralesional injection with Candida antigen or bleomycin for recalcitrant lesions.

1. Diagnosis & Pathophysiology:
   • Diagnosis: Vitiligo (Non-segmental / Generalized vitiligo).
   • Pathophysiology: Progressive autoimmune destruction and loss of functional melanocytes in the epidermis and hair follicles, mediated by autoreactive $\text{CD8}^+$ cytotoxic T-lymphocytes producing interferon-gamma (IFN-$\gamma$) and CXCL10, coupled with intrinsic melanocyte cellular oxidative stress and genetic susceptibility.
2. Bedside Diagnostic Tool:
   • Wood's Lamp Examination (long-wave UVA, peak wavelength $\approx 365\text{ nm}$):
   • Finding: Chalky, bright blue-white fluorescence with sharp enhancement of lesion margins (accentuation results from total absence of epidermal melanin to absorb UVA light).
3. Endocrine Associations & Screening:
   • Associated Conditions: Autoimmune thyroid disease (Hashimoto thyroiditis, Graves disease; occurs in up to 20%–30% of cases), Type 1 Diabetes Mellitus, Addison disease, and Polyglandular Autoimmune Syndromes.
   • Baseline Laboratory Screening:
     • Serum Thyroid Stimulating Hormone ($\text{TSH}$) and Free $\text{T}_4$.
     • Anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin (anti-TG) antibodies.
     • Fasting blood glucose or $\text{HbA}_{1c}$.
4. Treatment Protocols:
   • First-Line Topical Therapy (Body and Extremities):
     • Mid- to high-potency topical corticosteroid (e.g., Mometasone furoate 0.1% cream or Fluticasone propionate 0.05% cream) applied once daily in intermittent cycles (e.g., 2–3 weeks on, 1 week off) to mitigate cutaneous atrophy.
   • Facial / Intertriginous Lesions:
     • Topical Calcineurin Inhibitors (TCIs): Tacrolimus 0.03%–0.1% ointment or Pimecrolimus 1% cream applied twice daily (steroid-sparing, safe on thin facial skin).
   • Phototherapy:
     • Targeted or whole-body Narrowband UVB ($\text{NB-UVB}$, $311\text{ nm}$) administered 2–3 times per week for widespread involvement ($>15\%\text{–}20\%$ body surface area) or disease refractory to topical regimens.

1. Diagnosis & Inheritance:
   • Diagnosis: Xeroderma Pigmentosum (XP).
   • Inheritance: Autosomal recessive.
2. Molecular Pathophysiology:
   • Defective Pathway: Nucleotide Excision Repair (NER) pathway (both Global Genome NER [GG-NER] and Transcription-Coupled NER [TC-NER]).
   • Mechanism: Inability of the cell to excise UV-induced DNA photoproducts—specifically cyclobutane pyrimidine dimers (CPDs) and 6-4 pyrimidine-pyrimidone photoproducts (6-4PPs). This results in transcription stalling, defective replication, unrepaired genomic mutations, and premature cellular apoptosis or neoplastic transformation.
3. Complementation Groups:
   • Eight complementation groups:
     • XP groups A through G (XP-A, XP-B, XP-C, XP-D, XP-E, XP-F, XP-G; encoding NER enzymes).
     • XP Variant (XP-V): Normal NER, but mutations in POLH encoding DNA polymerase eta ($\text{pol }\eta$), which is responsible for error-free translesion DNA synthesis.
4. Malignancies:
   • Cutaneous: Basal Cell Carcinoma (BCC), Squamous Cell Carcinoma (SCC), and Cutaneous Malignant Melanoma.
   • Ocular: Squamous cell carcinoma of the conjunctiva/cornea, ocular melanoma.
   • (Note: Cutaneous neoplasias typically manifest before 8–10 years of age, representing a $>1000$-fold increased risk compared to the general pediatric population).
5. Management:
   • Strict Photoprotection:
     • Broad-spectrum physical sunscreens with SPF $\ge 50$ and high UVA/UVB protection (PA++++), reapplied every 2 hours outdoors.
     • UV-protective clothing (UPF 50+), broad-brimmed hats, face shields, and wrap-around UV-blocking sunglasses with side coverage.
     • Application of UV-blocking transparent films on school, home, and automobile windows; replacement of fluorescent bulbs with non-UV light sources.
   • Surveillance:
     • Full-body dermatological and comprehensive ophthalmological surveillance every 3 to 6 months for early identification and surgical excision of premalignant actinic keratoses and malignancies.
   • Chemoprevention & Supplementation:
     • Oral retinoids (e.g., Isotretinoin $0.5\text{–}1\text{ mg/kg/day}$ or Acitretin) to reduce the incidence of new non-melanoma skin cancers.
     • Vitamin D supplementation ($800\text{–}1000\text{ IU/day}$) due to mandatory strict sun avoidance.
   • Neurological Monitoring: Regular neurodevelopmental and audiometric evaluations for progressive neurodegeneration (sensorineural hearing loss, microcephaly, ataxia; as seen in De Sanctis-Cacchione syndrome, classically XP-A).